Journal
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 24, Issue 5, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2022.11595
Keywords
epithelioid sarcoma; adrenal gland; immunotherapy; tumor mutation burden; case report
Categories
Funding
- Talents Training Plan of Huadong Hospital affiliated to Fudan University
- [HDGG2017021]
Ask authors/readers for more resources
This study reports a case of epithelioid sarcoma (ES) in the adrenal gland, which was identified and analyzed using immunohistochemistry and next-generation sequencing technology. Partial remission was achieved through the application of immune checkpoint inhibitors (ICI).
Epithelioid sarcoma (ES) is a rare and highly invasive soft tissue malignant tumor with uncertain histogenesis. The localization of ES in the adrenal gland is rather unusual. The present study reported a case of stage IV ES in the adrenal gland of a 28-year-old male. The tissue biopsy of adrenal and lung lesions revealed epithelioid cells. Immunohistochemistry indicated that the tumor cells were strongly positive for cytokeratin (CK)8, CK, epithelial membrane antigen (EMA), CD34 and programmed cell death protein 1 ligand (PD-L1) but negative for nuclear integrase interactor 1 expression. The next-generation sequencing technology was applied using peripheral blood, indicating a low tumor mutation burden of 4.11 mutations (Muts)/Mb and somatic mutations in SMARCB1. After diagnosis, the patient underwent unsuccessful palliative chemotherapy and radiotherapy. However, application of immune checkpoint inhibitors (ICIs) achieved partial remission and the overall survival reached 25 months. ICI monotherapy may be a feasible treatment for patients with ES with a strong expression of PD-L1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available